221 related articles for article (PubMed ID: 28279455)
1. Modelling the elimination of river blindness using long-term epidemiological and programmatic data from Mali and Senegal.
Walker M; Stolk WA; Dixon MA; Bottomley C; Diawara L; Traoré MO; de Vlas SJ; Basáñez MG
Epidemics; 2017 Mar; 18():4-15. PubMed ID: 28279455
[TBL] [Abstract][Full Text] [Related]
2. Modelling the impact of ivermectin on River Blindness and its burden of morbidity and mortality in African Savannah: EpiOncho projections.
Turner HC; Walker M; Churcher TS; Basáñez MG
Parasit Vectors; 2014 May; 7():241. PubMed ID: 24886747
[TBL] [Abstract][Full Text] [Related]
3. Elimination of transmission of onchocerciasis (river blindness) with long-term ivermectin mass drug administration with or without vector control in sub-Saharan Africa: a systematic review and meta-analysis.
Mutono N; Basáñez MG; James A; Stolk WA; Makori A; Kimani TN; Hollingsworth TD; Vasconcelos A; Dixon MA; de Vlas SJ; Thumbi SM
Lancet Glob Health; 2024 May; 12(5):e771-e782. PubMed ID: 38484745
[TBL] [Abstract][Full Text] [Related]
4. Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis.
Stolk WA; Walker M; Coffeng LE; Basáñez MG; de Vlas SJ
Parasit Vectors; 2015 Oct; 8():552. PubMed ID: 26489937
[TBL] [Abstract][Full Text] [Related]
5. River Blindness: Mathematical Models for Control and Elimination.
Basáñez MG; Walker M; Turner HC; Coffeng LE; de Vlas SJ; Stolk WA
Adv Parasitol; 2016; 94():247-341. PubMed ID: 27756456
[TBL] [Abstract][Full Text] [Related]
6. Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa.
Kim YE; Remme JH; Steinmann P; Stolk WA; Roungou JB; Tediosi F
PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003664. PubMed ID: 25860569
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.
Diawara L; Traoré MO; Badji A; Bissan Y; Doumbia K; Goita SF; Konaté L; Mounkoro K; Sarr MD; Seck AF; Toé L; Tourée S; Remme JH
PLoS Negl Trop Dis; 2009 Jul; 3(7):e497. PubMed ID: 19621091
[TBL] [Abstract][Full Text] [Related]
8. What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination?
Hamley JID; Blok DJ; Walker M; Milton P; Hopkins AD; Hamill LC; Downs P; de Vlas SJ; Stolk WA; Basáñez MG
Trans R Soc Trop Med Hyg; 2021 Mar; 115(3):269-280. PubMed ID: 33515042
[TBL] [Abstract][Full Text] [Related]
9. Uncertainty surrounding projections of the long-term impact of ivermectin treatment on human onchocerciasis.
Turner HC; Churcher TS; Walker M; Osei-Atweneboana MY; Prichard RK; Basáñez MG
PLoS Negl Trop Dis; 2013; 7(4):e2169. PubMed ID: 23634234
[TBL] [Abstract][Full Text] [Related]
10. Reaching the london declaration on neglected tropical diseases goals for onchocerciasis: an economic evaluation of increasing the frequency of ivermectin treatment in Africa.
Turner HC; Walker M; Churcher TS; Osei-Atweneboana MY; Biritwum NK; Hopkins A; Prichard RK; Basáñez MG
Clin Infect Dis; 2014 Oct; 59(7):923-32. PubMed ID: 24944228
[TBL] [Abstract][Full Text] [Related]
11. How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.
Verver S; Walker M; Kim YE; Fobi G; Tekle AH; Zouré HGM; Wanji S; Boakye DA; Kuesel AC; de Vlas SJ; Boussinesq M; Basáñez MG; Stolk WA
Clin Infect Dis; 2018 Jun; 66(suppl_4):S267-S274. PubMed ID: 29860291
[TBL] [Abstract][Full Text] [Related]
12. Proof-of-principle of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: final results of a study in Mali and Senegal.
Traore MO; Sarr MD; Badji A; Bissan Y; Diawara L; Doumbia K; Goita SF; Konate L; Mounkoro K; Seck AF; Toe L; Toure S; Remme JH
PLoS Negl Trop Dis; 2012; 6(9):e1825. PubMed ID: 23029586
[TBL] [Abstract][Full Text] [Related]
13. Does Increasing Treatment Frequency Address Suboptimal Responses to Ivermectin for the Control and Elimination of River Blindness?
Frempong KK; Walker M; Cheke RA; Tetevi EJ; Gyan ET; Owusu EO; Wilson MD; Boakye DA; Taylor MJ; Biritwum NK; Osei-Atweneboana M; Basáñez MG
Clin Infect Dis; 2016 Jun; 62(11):1338-1347. PubMed ID: 27001801
[TBL] [Abstract][Full Text] [Related]
14. Onchocerciasis-associated epilepsy in Maridi, South Sudan: Modelling and exploring the impact of control measures against river blindness.
Bhattacharyya S; Vinkeles Melchers NVS; Siewe Fodjo JN; Vutha A; Coffeng LE; Logora MY; Colebunders R; Stolk WA
PLoS Negl Trop Dis; 2023 May; 17(5):e0011320. PubMed ID: 37235598
[TBL] [Abstract][Full Text] [Related]
15. Onchocerca volvulus infection and serological prevalence, ocular onchocerciasis and parasite transmission in northern and central Togo after decades of Simulium damnosum s.l. vector control and mass drug administration of ivermectin.
Komlan K; Vossberg PS; Gantin RG; Solim T; Korbmacher F; Banla M; Padjoudoum K; Karabou P; Köhler C; Soboslay PT
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006312. PubMed ID: 29494606
[TBL] [Abstract][Full Text] [Related]
16. The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis Group.
NTD Modelling Consortium Onchocerciasis Group
Gates Open Res; 2019; 3():1545. PubMed ID: 31723729
[TBL] [Abstract][Full Text] [Related]
17. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
Cupp EW; Sauerbrey M; Richards F
Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
[TBL] [Abstract][Full Text] [Related]
18. Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective.
Cupp E; Sauerbrey M; Cama V; Eberhard M; Lammie PJ; Unnasch TR
Infect Dis Poverty; 2019 Jul; 8(1):50. PubMed ID: 31303176
[TBL] [Abstract][Full Text] [Related]
19. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
Tekle AH; Elhassan E; Isiyaku S; Amazigo UV; Bush S; Noma M; Cousens S; Abiose A; Remme JH
Parasit Vectors; 2012 Feb; 5():28. PubMed ID: 22313631
[TBL] [Abstract][Full Text] [Related]
20. Scaling-Down Mass Ivermectin Treatment for Onchocerciasis Elimination: Modeling the Impact of the Geographical Unit for Decision Making.
Stolk WA; Blok DJ; Hamley JID; Cantey PT; de Vlas SJ; Walker M; Basáñez MG
Clin Infect Dis; 2021 Jun; 72(Suppl 3):S165-S171. PubMed ID: 33909070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
